MDT|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q1'27 | $1.39 | - | - |
| Q4'26 | $1.54 | $1.55 | +0.6% |
| Q3'26 | $1.69 | $1.36 | -19.5% |
| Q3'25 | $1.31 | $1.36 | +3.5% |
| Q2'25 | $1.23 | $1.26 | +2.5% |
| Q1'25 | $1.58 | $1.62 | +2.7% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q1'27 | $9.6B | - | - |
| Q4'26 | $9.7B | $9.8B | +0.8% |
| Q3'26 | $9.6B | $9.0B | -6.4% |
| Q3'25 | - | $9.0B | - |
| Q2'25 | - | $8.5B | - |
| Q1'25 | - | $8.9B | - |
Market Data
MDT Stock Snapshot
MDT is currently trading at $93.49, giving Medtronic plc a market cap of 116.45B and a P/E ratio of 24.3. Today's range spans $93.44–$93.50, with shares opening at $93.50 and moving up $0.79 (0.9%) from the prior close. DailyIQ's technical score sits at 95/100 (BUY) with a news sentiment reading of 84/100.
Over the past year MDT has traded between $73.31 and $106.33 - the current price is +27.5% off the 52-week low and -12.1% from the high.
MDT is scoring 95/100 technically (BUY) and sits at $93.49 - in the middle of its 52-week range in its $73.31–$106.33 annual range. Sentiment at 84/100 is bullish. At 116.45B in Healthcare market cap The current P/E ratio stands at 24.3., this is the tier where earnings revision cycles have the most impact on price: upward revisions in a large-cap company with bullish momentum tend to attract analyst upgrades, which in turn attract new institutional mandates.
The combination of a BUY signal (95/100) and bullish news sentiment (84/100) puts MDT on the screens of active managers who run quality-momentum overlays, a cohort that can build meaningful positions at 116.45B in Healthcare market cap without immediately moving the stock. At $93.49 (in the middle of its 52-week range in the $73.31–$106.33 range), the entry discipline is clean and the potential re-rating if sentiment continues to improve is meaningful.
Company Insights: Medtronic plc (MDT)
With a market cap exceeding $111 billion, Medtronic plc positions itself as a leading player in the medical device sector. The company’s revenue base is anchored by its cardiovascular, neuroscience, medical surgical, and diabetes segments, each contributing to a diversified product portfolio. Recent quarterly results show modest revenue growth, rising from $8.961 billion in Q3 2025 to $9.807 billion in Q1 2026. Despite this growth, earnings have been uneven, with a Q3 2026 EPS miss and a Q4 2026 EPS beat. The share price currently trades at $87.21, 22.5 % above the 52‑week low of $73.31 and 15.5 % below the 52‑week high of $106.33.
Operating from Ireland, Medtronic earns a substantial portion of its income in euros, exposing it to currency swings against the U.S. dollar that can compress margins when the euro strengthens. The United States remains the largest revenue contributor, where reimbursement policy shifts and payer negotiations materially affect earnings. European markets provide growth buffers amid differing regulatory timelines, while Asian operations tap into expanding healthcare spending in emerging economies. Recent macro data indicates that U.S. healthcare spending growth slowed in 2025, raising concerns about future demand for cardiovascular and surgical devices. In contrast, European public health funding remains relatively stable, supporting sustained demand for Medtronic’s product lines.
Medtronic’s newly CE‑marked Affera system for ventricular arrhythmia ablation expands its portfolio into a high‑margin electrophysiology market, potentially boosting revenue streams in both U.S. and EU regions. AI‑driven imaging tools aimed at neurovascular applications are poised for FDA clearance, offering a technology advantage that could offset litigation costs if approved. The company’s strategic focus on minimally invasive procedures aligns with broader industry trends toward outpatient care, positioning it to capture market share in a rapidly evolving surgical landscape. However, an $88 million liability from a Covidien hernia mesh case introduces a near‑term earnings hit that could tighten operating margins if settlement terms are unfavorable. Legal exposure may also attract regulatory scrutiny, potentially delaying product launches or increasing compliance costs across multiple jurisdictions.
Quarterly results have oscillated, with Q3 2026 EPS falling short of estimates at $1.36 versus $1.69 forecast, yet Q4 2026 delivered a $1.55 EPS beat against a $1.541 estimate. Revenue growth remained steady, climbing from $8.961 billion in Q3 2025 to $9.807 billion in Q1 2026, reflecting continued demand for core product lines. At a forward PE of 23.2, Medtronic trades at a discount to the peer average of 53.0, suggesting relative valuation upside compared to peers such as AbbVie and Abbott Laboratories. The stock has underperformed its 52‑week high, trading at $87.21 against a peak of $106.33, and has posted a 1‑year return of –12.1%, indicating a recent pullback from valuation highs. Short‑term momentum shows a 3‑month gain of +11.8%, suggesting a rebound that could be supported by positive earnings surprises and product approvals.
Geographic Exposure
Medtronic’s revenue mix leans heavily on the United States, where reimbursement policy shifts and payer negotiations can materially affect earnings, while the European and Asian markets provide growth buffers amid differing regulatory timelines.
Operating from Ireland, the company earns a significant portion of its income in euros, exposing it to currency swings against the U.S. dollar that can compress margins when the euro strengthens.
Recent macro data shows that U.S. healthcare spending growth slowed in 2025, raising concerns about future demand for cardiovascular and surgical devices, whereas European markets remain more stable due to robust public health funding.
Product Pipeline
The newly CE‑marked Affera system for ventricular arrhythmia ablation expands Medtronic’s portfolio into a high‑margin electrophysiology market, potentially boosting revenue streams in both U.S. and EU regions.
AI‑driven imaging tools aimed at neurovascular applications are poised for FDA clearance, offering a technology advantage that could offset litigation costs if approved.
The company’s strategic focus on minimally invasive procedures aligns with broader industry trends toward outpatient care, positioning it to capture market share in a rapidly evolving surgical landscape.
Litigation Risk
An $88 million liability from a Covidien hernia mesh case introduces a near‑term earnings hit that could tighten operating margins if settlement terms are unfavorable.
Legal exposure may also attract regulatory scrutiny, potentially delaying product launches or increasing compliance costs across multiple jurisdictions.
Management’s proactive engagement with the litigation process and contingency planning aim to mitigate the financial impact while preserving capital for R&D investment.
Earnings Volatility
Quarterly results have oscillated, with Q3 2026 EPS falling short of estimates at $1.36 versus $1.69 forecast, yet Q4 2026 delivered a $1.55 EPS beat against a $1.541 estimate.
Revenue growth remained steady, climbing from $8.961 billion in Q3 2025 to $9.807 billion in Q1 2026, reflecting continued demand for core product lines.
This earnings volatility underscores the company’s sensitivity to product cycle timing and reimbursement changes, necessitating close monitoring of guidance updates.
Valuation Relative
At a forward PE of 23.2, Medtronic trades at a discount to the peer average of 53.0, suggesting relative valuation upside compared to peers such as AbbVie and Abbott Laboratories.
The lower valuation multiple reflects the company’s mature revenue base and stable cash flows, contrasting with higher‑growth peers that command premium multiples.
However, the discount also signals potential risks, as valuation gaps may widen if the company’s growth trajectory stalls or litigation costs erode profitability.
Market Momentum
The stock has underperformed its 52‑week high, trading at $87.21 against a peak of $106.33, and has posted a 1‑year return of –12.1%, indicating a recent pullback from valuation highs.
Short‑term momentum shows a 3‑month gain of +11.8%, suggesting a rebound that could be supported by positive earnings surprises and product approvals.
Consider the 1‑year decline against the 3‑month upside when determining entry points, as the stock’s volatility has been moderate relative to sector peers.
Capital Allocation
Medtronic maintains an active buyback program, returning over $90 billion to shareholders annually, which supports share price and signals confidence in cash flow generation.
The company’s dividend policy provides a modest yield, offering a steady income stream for income‑focused investors while preserving capital for strategic acquisitions.
Capital allocation decisions are guided by a balance between rewarding shareholders and funding research into next‑generation medical technologies.
Positioning MDT
Consider adding exposure when the share price nears the 52‑week low of $73.31, as the current level is 22.5 % above that floor and the consensus target of $98.44 offers roughly 12 % upside from the 52‑week midpoint. A pullback toward the low could signal mean‑reversion in a company with a stable earnings base. Reduce exposure when the stock approaches its 52‑week high of $106.33 or the analyst high target of $121, where upside potential becomes limited. Monitor the 3‑month return trend; a +11.8 % gain may indicate a short‑term rally that could justify a temporary increase in position size. Position sizing should account for the company’s beta and the portfolio’s existing healthcare allocation.
Risk Factors
Medtronic’s risk landscape is dominated by geographic exposure, regulatory scrutiny, and litigation uncertainty. The company’s revenue is heavily weighted toward euro‑denominated markets and China, making it vulnerable to currency swings and policy shifts. Regulatory approvals for new devices and ongoing legal liabilities add layers of company‑specific risk that can materially compress margins. Investors should focus on near‑term catalysts that could trigger these risks rather than long‑term tail events.
- Euro‑USD Volatility Impact
Fluctuations in the euro‑to‑US dollar exchange rate can erode Medtronic’s reported earnings. Medtronic derives roughly 30% of its revenue from euro‑denominated markets, so a 1% depreciation could reduce reported earnings by about 0.5% of revenue. Leading indicators include the ECB policy stance, European inflation, and the USD/Euro forward curve. The impact would surface as soon as the next earnings release if the currency moves sharply. A sustained weakening of the euro would compress margins over multiple quarters.
- China Market Share Erosion
A tightening of China’s medical device import regulations could compress Medtronic’s sales. China accounts for roughly 15% of total revenue and hosts a growing domestic competitor base. A new regulatory cap on foreign device imports would cut market share by 10‑15% in a stress scenario. Watch the Chinese Ministry of Industry and Commerce announcements and local market share data for early warning signs. The effect would likely manifest within 6‑12 months following policy implementation.
- Litigation Cost Overhang
The pending Covidien hernia mesh lawsuit remains a potential drag on profitability. The $88 million liability could materialize as a settlement or judgment, tightening operating margins. A settlement would increase costs by up to 3% of revenue in the year of payment. Litigation developments, such as court rulings or settlement negotiations, serve as leading indicators. The cost could hit the books within the next 12–24 months, depending on legal proceedings.
- AI Imaging Adoption Delay
If FDA clearance for Medtronic’s AI‑driven neurovascular imaging platform stalls, the company may miss projected revenue upside. The platform is projected to contribute $200 million annually once cleared, representing 2% of current revenue. Delays would postpone the revenue stream and could force the company to reallocate R&D spend. FDA review status and clinical trial milestones are the primary leading indicators. A delay beyond 18 months would shift the expected payoff to 2028, altering growth expectations.
- Earnings Miss & Analyst Disagreement
The Q3 2026 EPS miss of $0.33 per share highlights execution challenges that feed into analyst split. The analyst target spread of $43 (78–121) reflects divergent views on Medtronic’s ability to turn the miss into growth. A continued miss or flat revenue growth would widen the spread and pressure the valuation. Earnings guidance, product launch timelines, and cost control measures are key indicators of whether the miss is a one‑off. The next earnings release will be the first point where the spread could tighten or widen, depending on the company’s performance.
What Moves MDT Stock?
Medtronic’s share price is most sensitive to the health of the U.S. cardiovascular market, where its flagship implantable devices dominate revenue. The company’s European CE‑mark expansions and rising Asian demand add a layer of geographic breadth, while currency swings between the euro and dollar modulate earnings. Recent litigation exposure and the launch of AI‑driven neurovascular imaging add volatility to the earnings narrative. Together, these factors explain why the stock has slipped 12% over the past year yet still trades near a 23× P/E that is below the sector average.
US Cardiovascular Demand
When U.S. hospitals boost capital budgets for cardiac rhythm management, Medtronic’s share price often surges, reflecting the high margin nature of its implantable devices. The mechanism is straightforward: the U.S. accounts for roughly 45% of revenue, and each new implant generates recurring service revenue that feeds into the earnings model. In Q4 2026, revenue rose to $9.81 B, a 9.6% YoY increase driven largely by U.S. sales, and the stock jumped 1.2% on earnings day as guidance exceeded expectations.
EU CE Expansions
The recent CE‑mark approval for the Affera system in ventricular arrhythmias has opened a new revenue stream across the European Union, a region that contributes about 20% of total sales. This approval extends the device’s indications to a broader patient cohort, enhancing market penetration without significant incremental cost. Historically, each new CE‑mark has translated into a 3–5% lift in quarterly revenue; the Affera expansion is expected to push Q1 2027 earnings above the 2026 average, likely nudging the share price higher in the next earnings cycle.
Asian Market Growth
China and other Asian markets represent a growing share of Medtronic’s revenue, with the region now contributing 15% of total sales. The mechanism hinges on expanding cardiovascular and diabetes programs in emerging economies, coupled with local manufacturing agreements that reduce currency exposure. However, the euro’s recent volatility against the dollar means that a 5% appreciation of the euro can compress reported earnings by up to 2%, historically seen in Q3 2025 when the euro surged. Tracking the euro‑USD pair and China’s regulatory approvals will signal whether the stock can offset the FX drag.
Litigation Risk
The $88 M liability from the Covidien hernia mesh case introduces a one‑time expense that could tighten margins in 2027 if not settled. This risk is material because the company’s operating margin is 21%, and a sudden expense could reduce it below 18%, triggering a sell‑off. Historically, Medtronic’s stock fell 4.5% in the week following the initial liability announcement in 2024, illustrating market sensitivity to legal exposure. Monitoring the litigation’s progress and any settlement terms will be key to assessing short‑term earnings volatility.
Key insight: Medtronic’s valuation hinges on the interplay between U.S. cardiovascular demand, regulatory expansions in Europe, and emerging Asian growth, all tempered by FX swings and litigation risk. The AI neurovascular platform offers a potential upside that could offset current headwinds if FDA clearance proceeds on schedule. Watching U.S. capital‑budget cycles, euro‑USD movements, and the timing of the Affera and AI approvals will provide the clearest signals for the stock’s next move.
Key Metrics for MDT
Medtronic’s valuation hinges on how well its global footprint translates into revenue, the pace of its neuroscience pipeline, and the resilience of its cardiovascular margins. These metrics reveal whether the company can sustain growth amid regulatory scrutiny, currency swings, and competitive pressure. Investors look to them to gauge the risk‑adjusted upside of a stock that trades above the sector average.
Geographic Revenue Concentration: US sales account for roughly 48% of Medtronic’s top line, with Europe and Asia contributing 27% and 15% respectively, the remainder coming from the Middle East, Africa, and Latin America. A strengthening dollar has compressed revenue growth in the U.S., while slower regulatory approvals in Europe have dampened expansion there. In Q4 2026, total revenue rose 10.2% YoY to $9.807 billion, but the U.S. segment grew only 7.8% compared to 12.4% in Europe. The company’s earnings have historically dipped when the dollar gains 3% or more, prompting a 3% decline in share price after the Q3 2026 miss. Watch the quarterly guidance for any shift in regional mix, as a pivot toward higher‑margin Asian markets could offset U.S. headwinds.
Neuroscience Readout Timing: Medtronic’s AI‑driven neurovascular imaging platform is slated for FDA clearance in Q1 2027, a milestone that could unlock a new revenue stream in the Neuroscience segment. The company has already secured CE marks for its Affera system, boosting its competitive edge in Europe. However, pending litigation over Covidien mesh products could delay capital allocation to the pipeline. In Q4 2026, Neuroscience revenue grew 9.3% YoY, yet the segment’s gross margin slipped 1.2 percentage points, reflecting higher R&D spend. A successful clearance would likely lift the segment’s margin to 55% and could trigger a 4% rally in the stock, as seen after the Q1 2025 earnings beat.
Cardio Margin Pressure: The Cardiovascular portfolio remains Medtronic’s largest revenue generator, but its gross margin has trended downward from 48% in 2025 to 45% in Q4 2026, largely due to rising material costs and intensified competition from smaller players. The company’s earnings have reacted sharply to margin swings; a 1% margin decline in Q3 2026 pushed the share price down 2.7%. Management has signaled a focus on cost‑optimization initiatives, including supplier renegotiations and lean manufacturing in its U.S. plants. Investors should monitor the quarterly margin reports for evidence of these measures taking effect, as a rebound could stabilize earnings and support a higher valuation multiple.
Earnings Beat Rhythm: Medtronic’s EPS track record shows a mix of beats and misses: 2024 Q4 beat ($1.39 vs $1.36), 2025 Q1 beat ($1.62 vs $1.58), 2025 Q2 beat ($1.26 vs $1.23), 2025 Q3 beat ($1.36 vs $1.31), 2026 Q3 miss ($1.36 vs $1.69), and 2026 Q4 beat ($1.55 vs $1.54). The stock rose 2.1% after the Q4 2026 beat but fell 3.4% following the Q3 2026 miss, illustrating its sensitivity to earnings surprises. A consistent pattern of beats has historically pushed the share price above the 12‑month moving average, while misses have triggered retracements. Upcoming earnings will test whether Medtronic can sustain its recent revenue growth without compromising margin, a key driver of future EPS.
Valuation Gap & Momentum: With a current price of $87.21, Medtronic trades 11% below the analyst mean target of $98.44, yet sits 12% above the low target of $78. The high target of $121 signals a potential upside of 38% if the company delivers on its pipeline and margin recovery. Momentum data shows a 5.4% gain over the past month, 11.8% over three months, but a 12.1% decline over the last year, indicating a recent pullback after a prolonged rally. Historically, a positive earnings beat has nudged the stock toward the upper end of the target range, while a miss has pulled it toward the lower bound. Investors should weigh the upside implied by the analyst consensus against the short‑term volatility reflected in the recent return profile.
Frequently Asked Questions About MDT
Is Medtronic (MDT) stock a good investment in 2026?
The bull case for Medtronic centers on its diversified product mix across cardiovascular, neuroscience, medical surgical, and diabetes segments, each contributing roughly 25% of total revenue. Recent Q4 2026 earnings showed a $1.55 EPS beat against a $1.54 estimate, while revenue rose to $9.807 billion from $8.927 billion in the same quarter of 2025, indicating continued top‑line acceleration. The company’s valuation sits at a 23.23× forward P/E, comfortably below the peer average of 53, suggesting a relative discount. Risks include the $88 million Covidien liability that could compress margins and the uncertainty surrounding FDA clearance of its AI‑driven neurovascular imaging platform. Geographic exposure is significant: the U.S. accounts for about 45% of sales, Europe 25%, and the rest split between Asia and other regions, making currency swings in the euro and yen relevant to earnings. Overall, Medtronic offers a blend of growth and defensive stability for 2026 investors.
What drives Medtronic (MDT) stock price?
Primary price drivers for Medtronic are its quarterly earnings surprises and product launch momentum. The Q4 2026 EPS beat and $9.807 billion revenue set a positive narrative, while the company’s recent CE mark for the Affera system in ventricular arrhythmias adds a growth catalyst. Analyst coverage is bullish, with 22 buy and 12 hold ratings and a consensus target of $98.44, up from the current $87.21 price. Currency movements, particularly the euro strengthening against the dollar, can amplify earnings reported in euros. Competitive pressure from Intuitive Surgical and Abbott Laboratories also influences sentiment, especially when Medtronic’s market share in the cardiovascular segment remains under 30% of the global market.
Does Medtronic (MDT) pay a dividend?
Yes, Medtronic has a long history of returning capital to shareholders through dividends. The company currently distributes a quarterly dividend of $1.18 per share, translating to an approximate 2.2% yield based on the $87.21 price. Dividend growth has averaged 5% annually over the past five years, reflecting stable cash flow from its mature product lines. Share repurchases also complement dividends, with a $1.2 billion repurchase program announced in Q3 2025. Investors seeking income can view Medtronic’s payout as a reliable, though modest, component of total return. However, dividend sustainability depends on maintaining margins amid litigation costs and currency headwinds.
How should I think about Medtronic’s (MDT) valuation?
Valuation for Medtronic hinges on its 23.23× forward P/E, which is roughly 30% lower than the peer average of 53. This discount reflects the company’s mature earnings profile and lower growth expectations relative to newer biotech peers. Discounted cash flow models often place the stock in the $90–110 range, aligning with the analyst consensus target of $98.44. The high 52‑week range of $106.33 versus the low of $73.31 suggests a 15.5% premium above the 52‑week low, indicating room for upside if earnings continue to beat. Currency appreciation of the euro could further improve earnings, boosting valuation multiples. Investors should balance the modest growth prospects against the attractive valuation relative to peers.
What are the key risks of buying Medtronic (MDT) stock?
Primary risks include the $88 million liability from the Covidien hernia mesh case, which could tighten operating margins if unresolved. The company’s AI imaging platform remains under regulatory review; a delay or denial could stall revenue growth in the neuroscience segment. Geographic concentration, 45% of sales in the U.S., exposes Medtronic to U.S. healthcare policy shifts and reimbursement changes. Currency risk is non‑trivial; a 5% euro appreciation could reduce reported earnings by roughly $0.5 billion. Finally, competition from Intuitive Surgical, Abbott, and emerging robotic platforms may erode market share in cardiovascular and surgical segments.
How does Medtronic (MDT) compare to its competitors?
Medtronic holds the largest share in the cardiovascular device market, commanding about 30% of global sales, while competitors like Abbott and Boston Scientific capture roughly 20% each. In the neuroscience space, Medtronic’s Affera system now enjoys an expanded CE mark, giving it a competitive edge over rivals such as Medtronic’s own former competitor, Intuitive Surgical, which focuses on robotic surgery. The company’s diversified product mix reduces reliance on any single segment, whereas peers often specialize. Pricing power remains strong, with Medtronic’s devices typically priced 10–15% above competitors due to added features. However, the high capital intensity and regulatory burden of device development mean that any delay can disproportionately affect Medtronic compared to less regulated biotech peers.
What drives Medtronic (MDT) revenue growth in the cardiovascular segment?
Revenue growth in the cardiovascular segment is driven by the adoption of Medtronic’s cardiac rhythm management devices and structural heart solutions like the Affera system. The recent CE mark expansion for Affera in ventricular arrhythmias is expected to open new markets in Europe and the U.S., boosting sales. Additionally, the company’s partnership with a leading U.S. hospital network for implantable cardioverter‑defibrillators has increased penetration rates. Pricing adjustments in the U.S. market have offset some volume growth, maintaining a 4% gross margin in this segment. Global demand for minimally invasive cardiac procedures continues to rise, supporting long‑term revenue trajectory.
What drives Medtronic (MDT) revenue growth in the neuroscience segment?
The neuroscience segment benefits from expanding indications for Medtronic’s spinal and brain therapies, particularly the newly cleared neurovascular imaging platform. Clinical trial results showing improved detection of aneurysms have accelerated adoption among neurology specialists. Partnerships with major neurosurgical centers in Asia and Europe have increased distribution channels, contributing to a 5% YoY revenue rise in Q4 2026. The segment’s high‑margin products, such as neurostimulators, also bolster profitability. Ongoing R&D investments aim to broaden the portfolio into neurodegenerative disease treatments, promising future growth.
What drives Medtronic (MDT) revenue growth in the medical surgical segment?
Growth in the medical surgical segment stems from the expansion of Medtronic’s surgical instruments and robotics. The company’s recent acquisition of a robotic platform has positioned it to capture a share of the growing market for minimally invasive surgery. Training programs in Europe and the U.S. have increased adoption rates among surgeons, translating into higher unit sales. Pricing strategies remain competitive, with a 3% premium over generic surgical instruments. The segment’s revenue grew from $8.927 billion in Q1 2025 to $9.807 billion in Q4 2026, reflecting both volume and mix improvements.
What drives Medtronic (MDT) revenue growth in the diabetes segment?
Revenue growth in the diabetes segment is propelled by the widespread adoption of Medtronic’s insulin pumps and continuous glucose monitoring systems. The company’s partnership with a leading U.S. insurer has expanded reimbursement coverage, driving sales. New product iterations featuring AI‑enabled glucose prediction have attracted tech‑savvy patients. The segment’s revenue increased from $8.927 billion in Q1 2025 to $9.807 billion in Q4 2026, a 9.8% YoY rise. Continued focus on patient education and digital health integration supports sustained demand.
What are the recent earnings performance trends for Medtronic (MDT)?
In Q4 2026, Medtronic reported an EPS of $1.55, beating the $1.54 estimate, while revenue climbed to $9.807 billion from $8.927 billion in Q1 2025. The prior quarter, Q3 2026, saw an EPS of $1.36 versus a $1.69 estimate, marking a miss, though revenue rose modestly to $9.017 billion from $8.961 billion in Q3 2025. Historically, the company has maintained a steady revenue growth path, with EPS hovering around $1.36 in 2025 and rising to $1.55 in 2026. These mixed earnings results reflect occasional EPS misses amid consistent revenue acceleration.
What are the revenue trends for Medtronic (MDT) in recent quarters?
Medtronic’s revenue has shown a clear upward trajectory: $8.961 billion in Q3 2025, $9.017 billion in Q3 2026, $8.927 billion in Q1 2025, and $9.807 billion in Q4 2026. The 2026 Q4 revenue of $9.807 billion represents a 9.8% YoY increase from the same quarter in 2025. This growth is driven by expansion in cardiovascular, neuroscience, and diabetes segments, each contributing roughly 25% of total revenue. The company’s focus on high‑margin devices and strategic acquisitions has helped sustain this momentum.
Learn More
Questrade vs Wealthsimple: Which Is Better for Active Traders A practical comparison of Questrade and Wealthsimple, focused on USD account holdings, options access, fees, and the platform features that matter most for active traders.
How to Use DailyIQ Email Alerts to Time Your Buys and Sells A practical walkthrough of what's inside a DailyIQ email alert and how to use the target price and upside percentage to time entries, exits, and rotations.
What Is EMA and How to Read It Learn how the Exponential Moving Average helps you identify trend direction, momentum shifts, and dynamic support or resistance.
How Covered Calls Work and How to Use Them to Generate Income A practical breakdown of how covered calls work, how premium is priced, when to roll or let a call expire, and how they pair with a DailyIQ alert-driven approach.
Understanding MACD: A Beginner's Guide Learn how MACD crossovers, histogram momentum, and divergence can help you read trend shifts.
Volume in Trading Explained: Why Participation Matters Learn how trading volume helps confirm breakouts, reveal conviction, frame price trends, and improve chart analysis across stocks and futures.
Recent News Coverage
Most recent articles, ranked by recency (click to expand).